The roles of angiotensin (Ang) II as produced by two different enzymes, angiotensin-converting enzyme (ACE) and chymase, were investigated in a canine experimental model where intima hyperplasia was induced by balloon catheterization in the common carotid and femoral arteries. The animals received oral candesartan cilexetil (3 mg/kg) or enalapril (10 mg/kg) twice a day for 5 weeks. After 1 week of active drug therapy, the common carotid and femoral arteries were unilaterally injured by balloon catheterization. In the common carotid arteries, both ACE and chymase activities were increased by the injury, with the increase in chymase activities being greater than that in ACE activities. In the femoral arteries, ACE, but not chymase, activities were significantly increased by the injury. Both candesartan cilexetil and enalapril reduced blood
Introduction
Angiotensin (Ang) II is generated locally in the vascular wall, and is thought to be involved in vascular hypertrophy in hypertension, atherosclerosis, and restenosis after percutaneous transluminal coronary angioplasty (PTCA). Studies have shown that: (1) vascular hypertrophy is reduced by angiotensinconverting enzyme (ACE) inhibitors or Ang II receptor antagonists; [1] [2] [3] [4] (2) components of the reninangiotensin system, such as ACE, 5, 6 and angiotensinogen mRNA 7 are activated or increased in the area of vascular hypertrophy; and (3) Ang II promotes migration, proliferation, and hypertrophy of vascular smooth muscle cells, and generation of extracellular matrix, as seen in in vitro and in vivo models. [8] [9] [10] [11] Because intima hyperplasia after balloon injury could be reduced by treatment of ACE inhibitors in rats, 3 ACE inhibitors were expected to be effective in clinical use. However, ACE inhibitors failed to reduce the restenosis seen after clinical PTCA. 12 Furthermore, not only in humans but also in Correspondence: Dr Mizuo Miyazaki, Department of Pharmacology, Osaka Medical College, 2-7 Daigakumachi, TakatsukiCity, Osaka 569-8686, Japan pressure almost equally. Enalapril increased plasma renin activity more strongly than did candesartan cilexetil, and significantly decreased vascular and plasma ACE activities. Candesartan cilexetil significantly suppressed the formation of intima hyperplasia in both the carotid and femoral arteries, while enalapril significantly suppressed intima hyperplasia in the femoral, but not in the carotid arteries. These results indicate that local Ang II production by ACE and chymase is involved in the hyperplasia seen in injured intima, and the difference in the inhibitory action of candesartan and enalapril reflects the extent of contribution of each enzyme. The effect of the ACE inhibitor, enalapril, depended on the activity of ACE, whereas that of the Ang II receptor antagonist, candesartan, was independent of ACE activity.
baboons, 13 ACE inhibitors had no effects on the intima hyperplasia. We have found that in vascular tissues in rats and rabbits, Ang I is converted to Ang II by ACE alone, while in humans, monkeys, dogs, and hamsters, Ang I is possibly converted by both ACE and chymase. [14] [15] [16] These species-dependent pathways of vascular Ang II production strongly suggest the involvement of Ang II produced by chymase, and may be the cause of the apparent discrepant action of ACE inhibitors in the rat and human studies. Ang II-producing ability in human blood vessels is approximately 70% dependent on chymase, and only 30% dependent on ACE.
14 Therefore, ACE inhibitors alone are not able to totally inhibit Ang II production. We would expect Ang II receptor antagonists to be able to totally block the actions of Ang II, as their mechanism of action is independent of the Ang II-generating pathways.
In the present study, canine common carotid and femoral arteries, which possess the Ang II-producing enzyme chymase, were injured by balloon catheterization as a restenosis model after PTCA, and Ang II generation systems in the neointima areas were analysed. Furthermore, effects of an Ang II receptor antagonist, candesartan cilexetil, and an ACE inhibitor, enalapril, on the neointima hyperplasia, were compared to evaluate the efficacy of candesartan cilexetil in preventing restenosis after PTCA in humans.
Materials and methods

Procedures
The experimental procedures for animals were planned and conducted in accordance with the guidelines of Osaka Medical College. Male and female beagle dogs (about 1 year old and 10 kg in body weight) were divided into three groups. Each group (n = 11) was given either 3 mg/kg of candesartan cilexetil, 10 mg/kg of enalapril, or vehicle, by oral gavage. The drugs were suspended in an aqueous gum-arabic solution and administered twice a day (at about 8 am and 7 pm) for 5 weeks at a volume of 10 ml/kg. An additional 10 ml/kg of tap water was used for flushing the gavage tube.
One week after the initiation of dosing, the common carotid arteries and femoral arteries were injured unilaterally by balloon catheterization while the animals were under pentobarbital anesthesia (35 mg/kg, i.v.). A balloon catheter (4F) was inserted via the right thyroid artery into the right common carotid artery. The balloon was filled with water to distend the artery, and about 10 cm of the artery was injured internally. After removing the catheter, the thyroid artery was ligated. The left common carotid artery was not catheterized, although the surrounding tissues were carefully trimmed off. A balloon catheter (4F) was also inserted into the right peripheral femoral artery, and about 5 cm was injured similarly. After the injury, the catheter was removed and the incision was sutured. Blood samples were collected 3 and 10 h after dosing on the day before the animals were killed.
Four weeks after the balloon catheterization, blood pressure was directly measured while the animals were under pentobarbital anesthesia, 3 h after the final dosing. After measuring the blood pressure, we removed the femoral and common carotid arteries and trimmed loose connective tissues. For morphologic examination, five and ten spots were sampled from each injured tissue, and one and two spots were sampled from uninjured femoral and carotid arteries, respectively. The rest of the tissues were used for measuring ACE and chymase activities.
Measurement of ACE and chymase activities
The tissue extract was prepared from the sampled arteries as follows. The minced tissues were homogenised in 10 volumes of 20 mmol/L sodium-phosphate buffer (pH 7.4), kept at 4°C for 1 h and then centrifuged at 20 000 g at 4°C for 30 min. The pellet was then homogenised in 5 volumes of 10 mmol/L sodium-phosphate buffer (pH 7.4) containing 2 mol/L KCl and 0.1% Nonidet P-40, kept overnight at 4°C and centrifuged again. Aliquots of the supernatants were used for the parallel determination of ACE 17 and chymase 15 activities by our method reported previously.
For determination of ACE activities, the tissue extract was incubated with Hippuryl-His-Leu, which is a specific substrate for ACE, at 37°C. The cleaved hippuric acid was measured by using reversed-phase high-performance liquid chromatography (HPLC) (Hitachi, Tokyo, Japan), with RP-18T column (C18, 4 mm i.d. × 250 mm).
For determination of chymase activities, 0.02 ml aliquots of tissue extract were incubated for 1 h at 37°C with 0.77 mmol/L of angiotensin I in 100 mmol/L borate-phosphate buffer (pH 9.0) containing 5 mmol/L EDTA, 8 mmol/L dipyridyl, and 0.77 mmol/L diisopropyl fluorophosphate (DFP), as inhibitors for ACE and angiotensinases. After the incubation, the reaction was terminated by adding 0.15 ml of 15% trichloroacetic acid. After the samples were centrifuged at 20 000 g, 0.2-ml aliquots of the supernatants were reacted for 10 min with 2 ml of 1% o-phthalaldehyde in alkaline condition. The reaction was terminated with 0.2 ml of 6 N HCl. The fluorescence was measured at 340 nm excitation and 455 nm emission with a fluorospectrophotometer (Hitachi, F-2000, Tokyo, Japan). Blank determination was done with the addition of 1 mmol/L chymostatin. Separate standard curves were prepared with and without chymostatin for blank and incubated samples, respectively, because chymostatin slightly affected fluorescence.
Morphologic examination
Glass slide-mounted samples were stained (elastica van Gieson's stain) and morphologic analysis was done in non-embolised samples. Areas of the lumen, the intima, and the media of each arterial section were blindly measured using a morphologic analyser (SPICCA, Abionics, Tokyo, Japan), and a ratio of the intima to the intima and the media was calculated as a marker of hyperplasia. As the degree of hyperplasia varies in each section, even in the same artery, the maximal and the minimal values of the ratio in each artery were discarded, and the means of the rest of the values of the ratio (eight and three values of the ratio for injured carotid and femoral arteries, respectively) were used as the representative values for each artery.
Drugs
Candesartan cilexetil and enalapril were synthesised at Takeda Chemical Industries (Osaka, Japan). The remaining drugs and agents were purchased as follows: Hippuryl-His-Leu, His-Leu, angiotensin I, and chymostatin from the Peptide Institute, Inc (Osaka, Japan), hippuric acid, trichloroacetic acid, and diisopropyl fluorophosphate from Wako Pure Chemical Industries (Osaka, Japan), and dipyridyl and o-phthalaldehyde from Nakaraitesc Inc (Kyoto, Japan).
Statistical analysis
All values are expressed as means ± s.e.m. Biochemical values for the different groups were compared by one-way analysis of variance (ANOVA) and Dunnett's test. Morphologic values for the different groups were transformed in log and compared by ANOVA and Fisher's least significant difference (LSD) type test. Two-tailed P values of Ͻ0.05 were regarded to indicate statistical significance.
Results
Effects on blood pressure, heart rate, and plasma biochemical indices Table 1 shows effects of candesartan cilexetil and enalapril on blood pressure, heart rate and plasma biochemical indices in dogs. Mean blood pressures, obtained with the animals under anesthesia 3 h after dosing on the final day, were 148.5 mm Hg (n = 11) in the vehicle control group, 130.8 mm Hg (n = 11) in the candesartan cilexetil-treated group and 128.7 mm Hg (n = 11) in the enalapril-treated group. The magnitude of the hypotensive responses to both the drugs were almost equal at these doses. Neither drugs affected heart rate.
Plasma renin activity (PRA) at 3 h after administration on the day before dissection was significantly increased in both candesartan cilexetil and enalapril-treated dogs. Enalapril increased PRA about two times higher than did candesartan cilexetil, and the effect lasted more than 10 h, whereas candesartan cilexetil affected the PRA only briefly.
Enalapril treatment almost completely inhibited plasma ACE activities 3 and 10 h after dosing on the day before the dissection. Enalapril also inhibited ACE activities significantly in carotid and femoral arteries.
Arterial biochemical examination
Thrombotic embolisation occurred by 4 weeks after the balloon injury at the injured portion in three of Table 1 Effects of candesartan cilexetil and enalapril on blood pressure, heart rate, plasma renin and ACE activities and arterial ACE and chymase activities in the dog
Vehicle
Candesartan cilexetil Enalapril (3 mg/kg, twice daily) (10 mg/kg, twice daily)
Mean blood pressure (mm Hg) (n = 11) (n = 11) (n = 11) 3 hours 148.5 ± 3.3 130.8 ± 3.2** 128.7 ± 4.6** Heart rate (beat/min) (n = 11) (n = 11) (n = 11) 3 hours 195.6 ± 11.2 174.9 ± 11.0 187.0 ± 6.0 PRA (ng AI/ml per hour) (n = 11) (n = 11) (n = 11) 3 hours 0.82 ± 0.18 6.64 ± 2.58* 10.15 ± 1.12** 10 hours 0.56 ± 0.10 2.51 ± 0.70 7.96 ± 0.92
Plasma ACE activity (mU/ml) (n = 11) (n = 11) (n = 11) 3 hours 4.76 ± 0. Data are mean ± s.e.m., P Ͻ 0.01, vs vehicle group and *P Ͻ 0.05, **P Ͻ 0.01, vs uninjured group (Dunnett's test). PRA, plasma renin activity; AI, angiotensen I; ACE, angiotensin-converting enzyme; act, enzyme activity.
11 carotid arteries in both groups of dogs treated with candesartan cilexetil or vehicle, and in six of 11 carotid arteries in dogs treated with enalapril. Thrombotic embolisation was also observed in one and two of 11 femoral arteries in dogs treated with candesartan cilexetil and enalapril, respectively, and was not found in 11 vehicle-treated dogs. Therefore, embolised samples were excluded from the morphologic examination. As one femoral arterial was not isolated in the vehicle-treated group, 10 samples were subjected to morphologic analysis in this group. Both ACE and chymase activities were increased in all cases of injured carotid arteries, and the average activities were 2.5 and 3.7 times higher than those in normal arteries, respectively. In femoral arteries, however, while ACE activities were increased in all injured arteries, chymase activities were not increased in three of 10 injured femoral arteries, and no significant difference was found for chymase activities (Table 1, Figure 1 ). Enalapril almost completely inhibited the increase in ACE activities seen in injured arteries. Neither candesartan cilexetil nor enalapril affected the increase in chymase activities seen in the injured arteries.
Arterial morphologic examination
The balloon injury elicited remarkable neointima formation in both carotid and femoral arteries. The ratios of the intima areas to the intima and media areas in the cross-sections were increased by about Figure 1 Effects of balloon injury on angiotensin-converting enzyme (ACE) and chymase activities in canine-common carotid and femoral arteries. Both ACE and chymase activities were elevated by the injury in the common carotid arteries. The elevation in chymase activities was more remarkable than that in ACE activities. In the femoral arteries, ACE activities were elevated by the injury but chymase activities were not increased significantly. Circles and columns represent each and mean values, respectively. prot. = protein. **P Ͻ 0.05, vs uninjured (control) side (ANOVA and Dunnett's test): n = 8-10.
15% and 35%, respectively, 4 weeks after the balloon catheterization.
As shown in Figure 2 , candesartan cilexetil significantly lowered the value of ratio that represents the extent of hyperplasia in the injured common carotid arteries, but enalapril did not lower it significantly. In injured femoral arteries, both candesartan cilexetil and enalapril significantly inhibited hyperplasia.
Discussion
The present results demonstrated that: (1) the remarkable intima hyperplasia took place together with an increase of ACE and chymase activities after the balloon injury in carotid arteries; (2) candesartan cilexetil significantly inhibited the neointima hyperplasia in both injured arteries; and (3) enalapril was effective on femoral arteries (without increase of chymase activity), but not on carotid arteries (with increase of chymase activity). These findings indicate that the ACE and chymase induced locally by the balloon injury generated Ang II, which may promote migration and proliferation of smooth-muscle cells and also production of extracellular matrix, and consequently, induced neointima hyperplasia.
Candesartan cilexetil and enalapril had different effects in this model. Enalapril, at 10 mg/kg, significantly inhibited both plasma and vascular ACE activities. In addition, enalapril increased PRA about two times more strongly than did candesartan cilexetil at 3 h after dosing, and the effect lasted longer than that of candesartan cilexetil. This suggests that this dose of enalapril was sufficient for inhibition of the renin-angiotensin system, compared with candesartan cilexetil at 3 mg/kg. However, enalapril failed to suppress the intima hyperplasia in the common carotid arteries, and was effective only in femoral arteries. This might result from the inability of enalapril to inhibit chymase activity. In this study, both Ang II-generating enzymes were found to have increased activity in carotid arteries, but only ACE activity was significantly increased in femoral arteries after the injury. Although the exact reason of the difference is unknown, the extent of injury to femoral arteries may not be enough to induce chymase activity in this case. As a result, enalapril did not significantly inhibit the hyperplasia induced in the carotid arteries, but was effective in the femoral arteries.
The fact that chymase activities were more greatly increased by the injury than were ACE activities in the carotid artery may suggest a superiority for the role of chymase in this hyperplasia model. However, the values for chymase activities were about onetenth of those of ACE. It should be remembered that enzyme activities do not accurately reflect the in vivo function of the enzyme. In this case, a different substrate was used in each assay procedure; Hippuryl-His-Leu for ACE, and Ang I for chymase. The reason that the artificial substrate was used for the ACE assay was that EDTA, added into the assay system to inhibit angiotensinases to recover Ang II, the final assay product of this system, inhibited ACE itself. According to Cushman and Cheung, 18 V max of ACE purified from rabbit lungs was 22 times higher for Hippuryl-His-Leu than for Ang I. If this figure is applicable to canine-vascular ACE, then ACE for Ang I can generate only half or one-third the amount of Ang II that is generated by chymase. We should not, therefore, underestimate the role of chymase in the vascular Ang II formation. It should also be emphasised that Ang II generation depends on chymase more potently in human arteries than in canine arteries: Ang II-generating ratio of ACE to chymase is 30 to 70 in humans, whereas that value is 70 to 30 in canines.
14 This actual function of chymase may explain the reason why ACE inhibitors had no effect on preventing restenosis after clinical PTCA, in a setting where chymase is supposedly activated.
Candesartan cilexetil suppressed neointima hyperplasia more dramatically than did enalapril, even at the smaller dose for suppressing the renin angiotensin system estimated by the PRA. Therefore, candesartan cilexetil should have greater efficacy in preventing restenosis after clinical PTCA. The effect of an ACE inhibitor is ACE dependent, whereas that of an Ang II antagonist is irrespective of the origin of the Ang II.
